IAG Bio-Partnering Team to Attend Bio€quity Europe in Ghent, Belgium, 14-16 May 2018
Dr. Diana Roettger, Head of Scientific and Medical Affairs and Lead Bio-Partnering Analyst will attend Bio€quity Europe 2018 in Ghent, Belgium from May 14 – May 16 to discuss the increasing need for collaboration between the investors and biotechnology companies in development of new compounds and to introduce IAG’s platforms, targeted development strategies and risk-sharing business model.
IAG Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.
IAG biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.
The scope of discussions for this conference include:
– Development of clinical stage assets
– IP acquisition from the academic partners and biotech companies
– Investment partnerships
– Strategic collaborations
To find out more about IAG Bio-Partnering services or to schedule a meeting during Bio€quity, please send an email to firstname.lastname@example.org.
About Bio€quity Europe
Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected Presenting Companies. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from 24 nations attended Bio€quity Europe last year in Paris. To find out more about this conference click here.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com